AltheRx Presents Positive Phase II Results of Solabegron in Overactive Bladder at the American Urological Association Annual Meeting

MALVERN, Penn.--(BUSINESS WIRE)-- AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the American Urological Association Annual Meeting (Abstract # 520). Solabegron is a novel beta3-adrenoceptor agonist with high affinity and selectivity that is in late stage clinical development for the treatment of OAB and irritable bowel syndrome (IBS).